MediMabBio is a biotherapeutic company that focuses on the generation of novel immunotherapies for the treatment of cancer.
MediMabBio has raised $17.8M in total funding. The most recent round was Series B. The last funding was announced in October 2025.
MediMabBio's investors include HLB Biostep, KB Investment, Yuanta Investment, Seoul Investment Partners, Smilegate Investment.
MediMabBio is headquartered in Seongnam, South Korea.
MediMabBio is a biotherapeutic company that focuses on the generation of novel immunotherapies for the treatment of cancer.
MediMabBio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"MediMabBio — Funding & Investors." VCBacked, October 24, 2025, https://www.vcbacked.co/company/medimabbio. Accessed July 19, 2026.
VCBacked. (2025). MediMabBio — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/medimabbio
{{cite web |title=MediMabBio — Funding & Investors |url=https://www.vcbacked.co/company/medimabbio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated